Key result
The PASAP-ILERVAS algorithm significantly improved the prediction of severe atheromatosis compared to the SCORE model in low- and high-risk women, demonstrating a net reclassification index of 0.193.
Why the study?
European guidelines recommend vascular ultrasound to assess cardiovascular risk in low-to-moderate risk individuals, but no algorithm identifies who would benefit, especially women who are usually underdiagnosed.
Does the PASAP-ILERVAS algorithm improve the prediction of severe atheromatosis compared to the SCORE model in asymptomatic middle-aged individuals?
Cohort (n=8,889)
Yes
Does the PASAP-ILERVAS algorithm improve the prediction of severe atheromatosis compared to the SCORE model in asymptomatic middle-aged individuals?
The PASAP-ILERVAS machine learning algorithm improves the prediction of severe atheromatosis compared to the SCORE model, particularly in women, potentially optimizing the selection of patients for vascular ultrasound screening.
Sex-specific algorithm may identify low-to-moderate risk patients for vascular ultrasound; leaves open prospective validation before clinical use.
Background Although European guidelines recommend vascular ultrasound for the assessment of cardiovascular risk in low-to-moderate risk individuals, no algorithm properly identifies patients who could benefit from it. The aim of this study is to develop a sex-specific algorithm to identify those patients, especially women who are usually underdiagnosed. Methods Clinical, anthropometrical, and biochemical data were combined with a 12-territory vascular ultrasound to predict severe atheromatosis (SA: ≥ 3 territories with plaque). A Personalized Algorithm for Severe Atheromatosis Prediction (PASAP-ILERVAS) was obtained by machine learning. Models were trained in the ILERVAS cohort ( n = 8,330; 51% women) and validated in the control subpopulation of the NEFRONA cohort ( n = 559; 47% women). Performance was compared to the Systematic COronary Risk Evaluation (SCORE) model. Results The PASAP-ILERVAS is a sex-specific, easy-to-interpret predictive model that stratifies individuals according to their risk of SA in low, intermediate, or high risk. New clinical predictors beyond traditional factors were uncovered. In low- and high-risk (L&H-risk) men, the net reclassification index (NRI) was 0.044 (95% CI: 0.020–0.068), and the integrated discrimination index (IDI) was 0.038 (95% CI: 0.029–0.048) compared to the SCORE. In L&H-risk women, PASAP-ILERVAS showed a significant increase in the area under the curve (AUC, 0.074 (95% CI: 0.062–0.087), p -value: < 0.001), an NRI of 0.193 (95% CI: 0.162–0.224), and an IDI of 0.119 (95% CI: 0.109–0.129). Conclusion The PASAP-ILERVAS improves SA prediction, especially in women. Thus, it could reduce the number of unnecessary complementary explorations selecting patients for a further imaging study within the intermediate risk group, increasing cost-effectiveness and optimizing health resources. Clinical Trial Registration [ www.ClinicalTrials.gov ], identifier [NCT03228459].
No takes yet. Share an insight, caveat, or question.
Bermúdez-López et al. (2022) conducted a cohort in Severe atheromatosis (n=8,889). PASAP-ILERVAS algorithm vs. SCORE model was evaluated on Net reclassification index (NRI) for severe atheromatosis prediction in low- and high-risk women (NRI 0.193, 95% CI 0.162-0.224, p=<0.001). The PASAP-ILERVAS algorithm significantly improved the prediction of severe atheromatosis compared to the SCORE model in low- and high-risk women, demonstrating a net reclassification index of 0.193.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: